AstraZeneca

Genetic mutations of EGFR-TK confer responsiveness to Iressa

Published in Oncology Business Week, May 30th, 2004

AstraZeneca provided comments about the research published recently regarding the analysis of mutations in tumor samples from non-small cell lung cancer (NSCLC) patients treated with Iressa (gefitinib).

The research signals major progress towards understanding which patients are likely to show significant tumor shrinkage in response to treatment with Iressa, the novel treatment for NSCLC targeted at epidermal growth factor tyrosine kinase (EGFR-TK). Two independent research groups in the U.S. suggest that patients who achieve tumor shrinkage of greater than 50% with Iressa are those where the site coding for EGFR-TK has been changed as a result of one or more mutations...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-05-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry